Vabysmo and Vitreous floaters - a phase IV clinical study of FDA data

Summary:

Vitreous floaters is reported as a side effect among people who take Vabysmo (faricimab-svoa), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Eylea, and have Diabetic retinal oedema.

The phase IV clinical study analyzes which people have Vitreous floaters when taking Vabysmo. It is created by eHealthMe based on reports of 1,424 people who have side effects when taking Vabysmo from the FDA, and is updated regularly.

What is Vabysmo?

Vabysmo has active ingredients of faricimab-svoa. eHealthMe is studying from 1,425 Vabysmo users. Check the latest studies of Vabysmo.

What is Vitreous floaters?

Vitreous floaters (spots before the eyes) is found to be associated with 834 drugs and 838 conditions by eHealthMe. Check the latest studies of Vitreous floaters.

On Jul, 19, 2026

1,424 people reported to have side effects when taking Vabysmo.
Among them, 60 people (4.21%) have Vitreous floaters.

Among these 60 people:

How long have people been on Vabysmo when they have Vitreous floaters? *

What is the gender of people who have Vitreous floaters when taking Vabysmo? *

female: 64.1 %
male: 35.9 %

What is the age of people who have Vitreous floaters when taking Vabysmo? *

What are other drugs people take besides Vabysmo? *

What are other side effects people have besides Vitreous floaters? *

Eye Inflammation: 9 people, 15.00%
Vision Blurred: 9 people, 15.00%
Visual Impairment: 6 people, 10.00%
Uveitis (inflammation of the uvea): 6 people, 10.00%
Eye Pain: 5 people, 8.33%
Intraocular Pressure Increased: 4 people, 6.67%
Vitritis (inflammation of the vitreous humour of the eye): 3 people, 5.00%
Iridocyclitis (inflammation of the iris and ciliary body of the eye): 3 people, 5.00%
Blindness: 3 people, 5.00%
Eye Disorder: 2 people, 3.33%

What are the existing conditions these people have? *

Diabetic Retinal Oedema (excessive build-up of fluid in the retina due to diabetes): 4 people, 6.67%
Macular Degeneration (painless eye condition that leads to the gradual loss of central vision): 3 people, 5.00%
High Blood Pressure: 2 people, 3.33%
High Blood Cholesterol: 2 people, 3.33%
Age-Related Macular Degeneration: 2 people, 3.33%
Stable Angina (a constant chest pain): 1 person, 1.67%
Neuropathy Peripheral (surface nerve damage): 1 person, 1.67%
Migraine (headache): 1 person, 1.67%
Intraocular Pressure Increased: 1 person, 1.67%
Indigestion: 1 person, 1.67%

* Approximation only. Some reports may have incomplete information.

Do you take Vabysmo and have Vitreous floaters?

- Check whether Vitreous floaters is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Vabysmo:

Vabysmo (1,425 reports)

Browse all side effects of Vabysmo:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Vitreous floaters:

Vitreous floaters (834 drugs)

Browse all the conditions that are associated with Vitreous floaters:

Vitreous floaters (838 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on faricimab-svoa (the active ingredients of Vabysmo) and Vabysmo (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.